Compounds > cholest-5-en-3-one
Page last updated: 2024-11-12

cholest-5-en-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cholest-5-en-3-one : A 3-oxo Delta(5)-steroid that is cholesterol in which the alcoholic hydroxy group has been oxidised to the corresponding ketone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9908107
CHEMBL ID307301
CHEBI ID63906
SCHEMBL ID288930
MeSH IDM0213301

Synonyms (26)

Synonym
601-54-7
5-cholesten-3-one
cholest-5-en-3-one
nsc 118979
einecs 210-004-6
delta(sup 5)-cholestenone
chebi:63906 ,
CHEMBL307301
cholestenone (delta 5)
LMST01010248
3-ketocholesterol
3-keto cholesterol
AKOS016006104
unii-58d45d7t5h
58d45d7t5h ,
BP-13156
delta(5)-cholestenone
3-oxocholest-5-ene
5-cholestenone
SCHEMBL288930
DTXSID40208841
.delta.5-cholesterone
.delta.5-cholesten-3-one
Q27132907
C90310
5-cholesten-3-on
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3-oxo-Delta(5)-steroidAny 3-oxo steroid which also contains a double bond between positions 5 and 6.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
superpathway of cholesterol degradation II (cholesterol dehydrogenase)3058
superpathway of cholesterol degradation I (cholesterol oxidase)1755
cholesterol degradation to androstenedione I (cholesterol oxidase)1931
cholesterol degradation to androstenedione II (cholesterol dehydrogenase)1334

Bioassays (14)

Assay IDTitleYearJournalArticle
AID51775Steady-state kinetic parameter on wild-type cholesterol oxidase1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase.
AID7634Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID113559Evaluated for potency in CDF1 mice and the ability of it to decrease feed consumption was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID51774Steady-state kinetic parameter on E361D mutant cholesterol oxidase1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase.
AID7635Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID51773Steady-state kinetic parameter on wild-type cholesterol oxidase1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase.
AID51772Steady-state kinetic parameter on E361D mutant cholesterol oxidase1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
The importance of GLU361 position in the reaction catalyzed by cholesterol oxidase.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID226241Feed efficiency was calculated by dividing body weight gain by feed consumption in mouse1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID108710Compound was evaluated for its potency in CDF1 mice and the abdominal fat weight was determined.1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID110288Evaluated for potency in CDF1 mice and the inhibition of body weight gain was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID7636Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.
AID1239268Protection against oxygen-glucose deprivation-induced cytotoxicity in Sprague-Dawley rat cerebral cortex primary neuronal cell cultures assessed as increase in cell viability at 0.1 to 250 uM added at onset of recovery period by MTT assay2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
CholesteroNitrones for Stroke.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		1.9910elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		1.9910amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
asparagine
Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group.		1.9910amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		1.9910amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9910dihydrogen
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		1.9910glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
cholest-4-en-3-one
cholest-4-en-3-one : A cholestanoid that is cholest-4-ene substituted by an oxo group at position 3.		2.7303-oxo-Delta(4) steroid;
cholestanoid		human metabolite;
plant metabolite
4,6-cholestadien-3-one
[no description available]		1.99103-oxo-Delta(4) steroid;
cholestanoid
24-ethyl-4-cholesten-3-one
stigmast-4-en-3-one: from the bark of Anacardium occidentale (cashew); structure in first source		1.9910C29-steroid;
steroid		metabolite
disufenton sodium
disufenton sodium: a nitrone benzene bissulfonate in development for stroke; has neuroprotective activity; structure in first source		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Weight Gain
Increase in BODY WEIGHT over existing weight.		01.9910
Apoplexy
[description not available]		02.1110
Cerebral Ischemia
[description not available]		02.1110
Anterior Circulation Transient Ischemic Attack
[description not available]		02.1110
Nervous System Disorders
[description not available]		02.1110
Injury, Ischemia-Reperfusion
[description not available]		02.1110
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.1110
Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)		02.1110
Nervous System Diseases
Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.		02.1110
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.1110
Stroke
A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)		02.1110